Evidence map›Paper›PMID 30939150›Full record

ArticlePloS one2019

Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan.

Pin-Hui Lee, Pei-Chun Chan, Yen-Ting Peng, Po-Wei Chu, Mei-Hua Wu, Ruwen Jou, Ming-Chih Yu, Chou-Jui Lin, Yi-Wen Huang, Shun-Tien Chien and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pin-Hui LeeTaiwan Centers for Disease Control, Taipei, Taiwan.
Pei-Chun ChanTaiwan Centers for Disease Control, Taipei, Taiwan.
Yen-Ting PengTaiwan Centers for Disease Control, Taipei, Taiwan.
Po-Wei ChuTaiwan Centers for Disease Control, Taipei, Taiwan.
Mei-Hua WuTaiwan Centers for Disease Control, Taipei, Taiwan.
Ruwen JouTaiwan Centers for Disease Control, Taipei, Taiwan.
Ming-Chih YuDivision of Pulmonary Medicine, Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
Chou-Jui LinPulmonary and Critical Care Unit, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.
Yi-Wen HuangPulmonary and Critical Care Unit, Changhua Hospital, Ministry of Health and Welfare, Changhua, Taiwan.
Shun-Tien ChienPulmonary and Critical Care Unit, Chest Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
Jen-Jyh LeeDepartment of Internal Medicine, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan.
Chen-Yuan ChiangDivision of Pulmonary Medicine, Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-9291-2490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) patients in the 1990s in Taiwan was not satisfactory. To strengthen programmatic management of drug-resistant tuberculosis (PMDT), Taiwan MDR-TB Consortium (TMTC) was established in 2007. We assess the performance and epidemiologic impact of TMTC. METHODOLOGY/PRINCIPLE

findingsWe analyzed the trends of proportion of TB cases with drug susceptibility testing, enrollment of MDR-TB patients into TMTC and outcomes of treatment of all MDR-TB patients in Taiwan from 2007-2016. We computed the trends of both incidence and prevalence of MDR-TB from 2007-2016. We assessed the trends of MDR-TB among both new and recurrent TB cases. The proportion of TB cases with drug susceptibility testing results increased from 24.2% in 2007 to 97.9% in 2016. Of the 1,452 MDR-TB patients who were eligible for TMTC care, 1,197 (82.4%) were enrolled in TMTC, in whom 82.9% had treatment success. MDR-TB incidence was 9.0 cases per million in 2007, which declined to 4.6 cases per million in 2016 (p<0.0001). MDR-TB prevalence decreased from 19.4 cases per million in 2007 to 8.4 cases per million in 2016 (p<0.0001). The proportion of MDR-TB among new TB cases decreased from 1.4% in 2010 to 1.0% in 2016 (p = 0.039); and that among recurrent TB cases from 9.0% in 2010 to 1.8% in 2016 (p<0.0001).

conclusionsWe concluded that effective PMDT have had a significant impact on the epidemic of drug-resistant TB in Taiwan.

Indexed as

Microbial Sensitivity TestsAdultAgedAntitubercular AgentsDirectly Observed TherapyFemaleHumansIncidenceMaleMiddle AgedMycobacterium tuberculosisTaiwanTreatment OutcomeTuberculosis, Multidrug-ResistantYoung AdultAntitubercular Agents

Identifiers

PMID30939150
PMCPMC6445419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.